Suven Pharmaceuticals Limited Asset Resilience Ratio
Suven Pharmaceuticals Limited asset resilience ratio. Suven Pharmaceuticals Limited (SUVENPHAR) has an Asset Resilience Ratio of 6.76% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Suven Pharmaceuticals Limited defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Suven Pharmaceuticals Limited (2019–2025)
Asset resilience ratio of Suven Pharmaceuticals Limited from 2019 to 2025. This chart shows how Suven Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. Read SUVENPHAR total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Suven Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Suven Pharmaceuticals Limited balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs2.05 Billion | 6.76% |
| Total Liquid Assets | Rs2.05 Billion | 6.76% |
Asset Resilience Insights
- Limited Liquidity: Suven Pharmaceuticals Limited maintains only 6.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Suven Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare Suven Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Suven Pharmaceuticals Limited Asset Resilience Ratio by Year (2019–2025)
Suven Pharmaceuticals Limited asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Suven Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 6.76% | Rs2.05 Billion ≈ $22.17 Million |
Rs30.32 Billion ≈ $327.87 Million |
-27.57pp |
| 2024-03-31 | 34.33% | Rs7.74 Billion ≈ $83.69 Million |
Rs22.54 Billion ≈ $243.77 Million |
+12.84pp |
| 2023-03-31 | 21.49% | Rs4.22 Billion ≈ $45.68 Million |
Rs19.66 Billion ≈ $212.59 Million |
-4.81pp |
| 2022-03-31 | 26.30% | Rs4.81 Billion ≈ $52.04 Million |
Rs18.30 Billion ≈ $197.86 Million |
+14.05pp |
| 2021-03-31 | 12.25% | Rs1.81 Billion ≈ $19.53 Million |
Rs14.74 Billion ≈ $159.46 Million |
+9.63pp |
| 2020-03-31 | 2.62% | Rs306.76 Million ≈ $3.32 Million |
Rs11.73 Billion ≈ $126.84 Million |
+1.71pp |
| 2019-03-31 | 0.90% | Rs70.64 Million ≈ $763.92K |
Rs7.83 Billion ≈ $84.68 Million |
-- |
About Suven Pharmaceuticals Limited
Cohance Lifesciences Limited engage in the end-to-end contract development and manufacturing of intermediates and active pharmaceutical ingredients in India. The coampny offers active pharmaceutical ingredients and formulations for various applications; CDMO services, a flexible and custom solutions for challenging development and manufacturing needs; and clinical, analytical, and research servic… Read more